Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene-Driven Myeloid Leukemia.

Lopez CK, Noguera E, Stavropoulou V, Robert E, Aid Z, Ballerini P, Bilhou-Nabera C, Lapillonne H, Boudia F, Thirant C, Fagnan A, Arcangeli ML, Kinston SJ, Diop M, Job B, Lecluse Y, Brunet E, Babin L, Villeval JL, Delabesse E, Peters AHFM, Vainchenker W, Gaudry M, Masetti R, Locatelli F, Malinge S, Nerlov C, Droin N, Lobry C, Godin I, Bernard OA, Göttgens B, Petit A, Pflumio F, Schwaller J, Mercher T.

Cancer Discov. 2019 Dec;9(12):1736-1753. doi: 10.1158/2159-8290.CD-18-1463. Epub 2019 Oct 29.

PMID:
31662298
2.

Chromosomal Translocation Formation Is Sufficient to Produce Fusion Circular RNAs Specific to Patient Tumor Cells.

Babin L, Piganeau M, Renouf B, Lamribet K, Thirant C, Deriano L, Mercher T, Giovannangeli C, Brunet EC.

iScience. 2018 Jul 27;5:19-29. doi: 10.1016/j.isci.2018.06.007. Epub 2018 Jun 19.

3.

Molecular pathways driven by ETO2-GLIS2 in aggressive pediatric leukemia.

Thirant C, Lopez C, Malinge S, Mercher T.

Mol Cell Oncol. 2017 Sep 26;4(6):e1345351. doi: 10.1080/23723556.2017.1345351. eCollection 2017.

4.

ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia.

Thirant C, Ignacimouttou C, Lopez CK, Diop M, Le Mouël L, Thiollier C, Siret A, Dessen P, Aid Z, Rivière J, Rameau P, Lefebvre C, Khaled M, Leverger G, Ballerini P, Petit A, Raslova H, Carmichael CL, Kile BT, Soler E, Crispino JD, Wichmann C, Pflumio F, Schwaller J, Vainchenker W, Lobry C, Droin N, Bernard OA, Malinge S, Mercher T.

Cancer Cell. 2017 Mar 13;31(3):452-465. doi: 10.1016/j.ccell.2017.02.006.

5.

A cell-penetrating peptide based on the interaction between c-Src and connexin43 reverses glioma stem cell phenotype.

Gangoso E, Thirant C, Chneiweiss H, Medina JM, Tabernero A.

Cell Death Dis. 2014 Jan 23;5:e1023. doi: 10.1038/cddis.2013.560.

6.

Sirtuin-2 activity is required for glioma stem cell proliferation arrest but not necrosis induced by resveratrol.

Sayd S, Thirant C, El-Habr EA, Lipecka J, Dubois LG, Bogeas A, Tahiri-Jouti N, Chneiweiss H, Junier MP.

Stem Cell Rev Rep. 2014 Feb;10(1):103-13. doi: 10.1007/s12015-013-9465-0.

PMID:
23955573
7.

Critical multiple angiogenic factors secreted by glioblastoma stem-like cells underline the need for combinatorial anti-angiogenic therapeutic strategies.

Thirant C, Gavard J, Junier MP, Chneiweiss H.

Proteomics Clin Appl. 2013 Jan;7(1-2):79-90. doi: 10.1002/prca.201200102. Review.

PMID:
23229792
8.

Differential proteomic analysis of human glioblastoma and neural stem cells reveals HDGF as a novel angiogenic secreted factor.

Thirant C, Galan-Moya EM, Dubois LG, Pinte S, Chafey P, Broussard C, Varlet P, Devaux B, Soncin F, Gavard J, Junier MP, Chneiweiss H.

Stem Cells. 2012 May;30(5):845-53. doi: 10.1002/stem.1062.

9.

Antiproliferative activity of trans-avicennol from Zanthoxylum chiloperone var. angustifolium against human cancer stem cells.

Cebrián-Torrejón G, Assad Kahn S, Lagarde N, Castellano F, Leblanc K, Rodrigo J, Molinier-Frenkel V, Rojas de Arias A, Ferreira ME, Thirant C, Fournet A, Figadère B, Chneiweiss H, Poupon E.

J Nat Prod. 2012 Feb 24;75(2):257-61. doi: 10.1021/np2004165. Epub 2012 Feb 3.

PMID:
22304006
10.

Collaboration between PcG proteins and MLL fusions in Leukemogenesis: an emerging paradigm.

Zeisig BB, Arteaga MF, Thirant C, So CW.

Cancer Cell. 2011 Nov 15;20(5):551-3. doi: 10.1016/j.ccr.2011.10.031.

11.

Proteomic analysis of oligodendrogliomas expressing a mutant isocitrate dehydrogenase-1.

Thirant C, Varlet P, Lipecka J, Le Gall M, Broussard C, Chafey P, Studler JM, Lacombe J, Lions S, Guillaudeau A, Camoin L, Daumas-Duport C, Junier MP, Chneiweiss H.

Proteomics. 2011 Nov;11(21):4139-54. doi: 10.1002/pmic.201000646. Epub 2011 Sep 22.

PMID:
21898821
12.

Functional analysis of HOXD9 in human gliomas and glioma cancer stem cells.

Tabuse M, Ohta S, Ohashi Y, Fukaya R, Misawa A, Yoshida K, Kawase T, Saya H, Thirant C, Chneiweiss H, Matsuzaki Y, Okano H, Kawakami Y, Toda M.

Mol Cancer. 2011 May 22;10:60. doi: 10.1186/1476-4598-10-60.

13.

Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway.

Galan-Moya EM, Le Guelte A, Lima Fernandes E, Thirant C, Dwyer J, Bidere N, Couraud PO, Scott MG, Junier MP, Chneiweiss H, Gavard J.

EMBO Rep. 2011 May;12(5):470-6. doi: 10.1038/embor.2011.39. Epub 2011 Apr 1.

14.

Clinical relevance of tumor cells with stem-like properties in pediatric brain tumors.

Thirant C, Bessette B, Varlet P, Puget S, Cadusseau J, Tavares Sdos R, Studler JM, Silvestre DC, Susini A, Villa C, Miquel C, Bogeas A, Surena AL, Dias-Morais A, Léonard N, Pflumio F, Bièche I, Boussin FD, Sainte-Rose C, Grill J, Daumas-Duport C, Chneiweiss H, Junier MP.

PLoS One. 2011 Jan 28;6(1):e16375. doi: 10.1371/journal.pone.0016375.

15.

CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors.

Patru C, Romao L, Varlet P, Coulombel L, Raponi E, Cadusseau J, Renault-Mihara F, Thirant C, Leonard N, Berhneim A, Mihalescu-Maingot M, Haiech J, Bièche I, Moura-Neto V, Daumas-Duport C, Junier MP, Chneiweiss H.

BMC Cancer. 2010 Feb 24;10:66. doi: 10.1186/1471-2407-10-66.

16.

Regulation of sensory neuron-specific acid-sensing ion channel 3 by the adaptor protein Na+/H+ exchanger regulatory factor-1.

Deval E, Friend V, Thirant C, Salinas M, Jodar M, Lazdunski M, Lingueglia E.

J Biol Chem. 2006 Jan 20;281(3):1796-807. Epub 2005 Oct 17.

Supplemental Content

Loading ...
Support Center